COMMUNIQUÉS West-GlobeNewswire

Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
28/07/2026
NEW HAVEN, Conn., July 28, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review [...]
Lungpacer Announces Health Economic Analysis Demonstrating Clinical and Cost Benefits of AeroPace in Mechanically Ventilated Patients
28/07/2026
Analysis projects national average cost savings of ~$24,000 per episode alongside improved ventilator weaning outcomes EXTON, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Lungpacer Medical today announced results from a new [...]
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML
28/07/2026
CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T [...]
Atea Pharmaceuticals Meets Both Its Primary and Secondary Endpoints in the Phase 3 C-BEYOND North America Trial Evaluating Bemnifosbuvir/Ruzasvir for Hepatitis C Virus
28/07/2026
Bemnifosbuvir/Ruzasvir (BEM/RZR) Achieved its Primary Endpoint of Statistical Non-inferiority Compared to Sofosbuvir/Velpatasvir (SOF/VEL; Epclusa ® ), a Standard-of-Care, in First-Ever Successful Head-to-Head Trial in [...]
Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026
28/07/2026
NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second [...]
Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
28/07/2026
Second quarter revenue of $204 million, a year-over-year increase of 12% as reported and 13% organic GAAP operating income increased 1% year-over-year while adjusted operating income increased 55% Raising both FY26 [...]
Antag Therapeutics Announces Dosing of First Patient in Phase 2a Trial of First-in-Class GIPR Antagonist AT7687
28/07/2026
The Phase 2a study will evaluate AT7687 as a differentiated combination treatment approach for people living with obesity and type 2 diabetes A 13-week study of 150 randomized participants receiving either once-weekly [...]
NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026
28/07/2026
CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
28/07/2026
Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial Important secondary endpoints were also met, including two-level [...]
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
28/07/2026
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial
28/07/2026
No ARIA-E observed across all genotypes, including APOE4 homozygotes ARIA-H tracking background rates Early biomarker movement consistent with target engagement 12-month topline results expected in Q1 2027 Cambridge, [...]
Starget Pharma Expands Scientific Advisory Board with Appointment of Two Global Leaders in Radiopharmaceutical Therapy
28/07/2026
Dr. Oliver Sartor brings more than 35 years advancing the clinical development and commercialization of oncology and radiopharmaceuticals Professor Michael Hofman brings more than 20 years pioneering molecular imaging [...]
Pluri Advances Commercial Expansion Through Its Subsidiary Cellav, Completing Regulatory Registration in the UK
28/07/2026
UK regulatory registration supports commercial launch of regenerative aesthetics portfolio in a marke t with an estimated size of ~$900 million annual ly , an d strengthens the foundation for broader international [...]
Enlivex Announces $400,000,000 Private Placement
28/07/2026
Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered [...]
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina’s Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
28/07/2026
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multiplex Platforms [...]
CorVascular Named Exclusive U.S. Importer and Vascular Distributor for ASUS FDA-Cleared Ultrasound Portfolio
28/07/2026
MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- CorVascular today announced its appointment as the exclusive U.S. importer and vascular market distributor for ASUS’s portfolio of FDA-cleared ultrasound devices. [...]
Pacira BioSciences Announces New National Survey Revealing the Hidden Toll of Pain on America’s Workforce
28/07/2026
- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - BRISBANE, Calif., July 28, 2026 (GLOBE NEWSWIRE [...]
Apyx Medical Corporation to Participate in the Canaccord Genuity 46th Annual Growth Conference
28/07/2026
CLEARWATER, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the the leader in surgical aesthetics marketed and sold as Renuvion® and the AYON Body [...]
New Survey: Digestive Side Effects Cause 41% of GLP-1 Users to Suffer in Silence, Self-Adjust, or Consider Quitting
28/07/2026
Of these users, 1 in 5 believe incorrectly that GI side effects are just the price to pay, while others are quietly adjusting their own doses or stopping these popular drugs NEW YORK , July 28, 2026 (GLOBE NEWSWIRE) -- [...]

Pages